



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b> C07K 13/00, 7/10, A61K 37/02 A61K 39/00	<b>A1</b>	<b>(11) International Publication Number:</b> WO 92/14756 <b>(43) International Publication Date:</b> 3 September 1992 (03.09.92)
<b>(21) International Application Number:</b> PCT/NO92/00032 <b>(22) International Filing Date:</b> 21 February 1992 (21.02.92) <b>(30) Priority data:</b> 9103974.3 26 February 1991 (26.02.91) GB <b>(71) Applicant (for all designated States except US):</b> NORSK HY- DRO A.S [NO/NO]; N-0242 Oslo (NO). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GAUDERNACK, Gus- tav [NO/NO]; Anthon Walles vei 17 A, N-1300 Sandvi- ka (NO). GEDDE-DAHL d.y., Tobias [NO/NO]; Strømstangsveien 10 A, N-1335 Snarøya (NO). ERIK- SEN, Jon, Amund [NO/NO]; Bjørntvedtgt. 37, N-3900 Porsgrunn (NO).	<b>(74) Agent:</b> DAHL, Elisabeth; Pronova a.s, Strandveien 5, N- 1324 Lysaker (NO). <b>(81) Designated States:</b> AT (European patent), AU, BE (Euro- pean patent), BG, CA, CH (European patent), CS, DE (European patent), DK (European patent), ES (Euro- pean patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European pa- tent), JP, KR, LU (European patent), MC (European pa- tent), NL (European patent), NO, PL, RO, RU, SE (Eu- ropean patent), US. <b>Published.</b> <i>With international search report.</i>	

**(54) Title:** THERAPEUTICALLY USEFUL PEPTIDES AND PEPTIDES FRAGMENTS**(57) Abstract**

Synthetic peptides and fragments of oncogene protein products which elicit T cellular immunity, for use in cancer vaccines and compositions for anti-cancer treatment.

**Protocol:**

2 million cells / ml x 10 ml

20 micrograms of five p21 ras peptides

1 week

restimulation: 1 million autologous feeder cells/ml

and 20 micrograms of each peptide final dilution

1 week

restimulation (as described above)

1 week

cloning: 20 Terasaid plates, 1 blast per well

clones in 51 out of 600 wells

Probability of clonality: 97.5 %

45 clones expanded

29 clones characterized

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

## THERAPEUTICALLY USEFUL PEPTIDES AND PEPTIDE FRAGMENTS.

### Summary of the invention

This invention relates to synthetic peptides and fragments of oncogene protein products which elicit T cellular immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising said peptides or peptide fragments.

### Prior art

From EP272321 it is known to use an oncogene protein product or a fragment thereof for the production of an immunoglobulin specific for the oncogene protein, and thereafter forming a conjugate of said immunoglobulin and an anti-cancer agent to be used in the treatment of cancer.

From EP177814 and EP175360 it is known to produce antibodies against oncogene protein products, such as the p21 protein of ras, only differing in one amino acid in position 12 from the normal protein product. These antibodies may be used for diagnostic or therapeutic purposes. In order to achieve immunogenic peptide fragments of the p21 ras protein, a cysteine residue is inserted between the positions 16 and 17, to which a protein carrier may be attached.

Further, from EP 253325, there are known oncogene-related peptides, which comprise a portion of the amino acid sequence coded for by an oncogene, and antibodies directed to said peptides.

It is further known that one approach to an immunological cancer therapy has been through administration of interleukin-2 combined with specific lymphocytes, so called lymphokine-activated killer cells (LAK cells), or tumour

infiltrating lymphocytes (TIL cells). The beneficial effects achieved for some patients having specific cancers are not of a general nature. Further, the side effects experienced by some of the patients are quite unpleasant and sometimes severe. (Steven A. Rosenberg, Scientific American, May 1990, Adoptive Immunotherapy for Cancer.)

It is also known that attempts have been made to develop cancer vaccines based on injection of cancer cells from the patients own cancer or insoluble fragments of said cells or such cells mixed with other nonspecific stimulators of the immune system, such as BCG, interferons or interleukins.

D.J. Peace et al, in Fed. Am. Soc. Exp.Biol. (1990) J4(7), p.A2013 Abstract No 1854, have published results of immunization of mice with a 5-16 fragment of p21 ras protein having a substitution of arginine for glycine at position 12. which resulted in T cell responses. The response was specific for the immunizing peptide and the T cells were capable of responding to the whole protein carrying the same Arg-12 substitution. These results demonstrate that ras peptides are immunogenic in the context of the H-2 molecules of the C57BL/6 mouse strain used in these experiments, and that antigen presenting cells of this mouse strain are capable of processing p21 ras to yield fragments cross reactive with the synthetic peptide used for immunization.

The finding that a mouse strain can be immunized is not relevant for the present invention for the following reasons:

It is a general observation in mice that strains with different H-2 types recognize different sets of peptides from the same protein, [S.S.Zamvil et al, J.Exp.Med, Vol. 168, (1988), 1181-1186], thus a peptide which elicits an immune response in a mouse of one strain, may not stimulate T cells from another, closely related mouse strain. Also in experimental models, T cells from mice, rats and human beings

are known to recognize different, non overlapping epitopes of the same protein. The explanation for this is thought to reside in differences between the species in their antigen processing machinery and peptide binding capabilities of their MHC molecules.

From Stefan Jung and Hermann J. Schleusener, J. Exp. Med., Vol. 173, Jan. 1991 it is reported that a synthetic peptide fragment of the amino acids 5-16 of the p21 ras protein having a valine instead of a glycine amino acid in position 12 is recognized by human CD4<sup>+</sup> T cells from two healthy persons and that these T cells may be generated as antigen specific T cell lines, which do not cross react with the corresponding peptides derived from the normal p21 ras proteins. In this work it is shown that the human immune system recognizes this single synthetic peptide fragment.

The relevance of this finding is, however unclear since it is known that T cell reactivity against synthetic peptides may differ from T cell reactivity against the whole protein from which the peptides were derived. The explanation for this discrepancy being that equivalents of the synthetic peptide are not formed during proteolytic cleavage/processing of the protein in vivo. Thus, it is of vital importance that the peptide fragment used will elicit specific T cell responses or evoke memory T cell responses to the actual oncogene protein fragment produced by processing and presented by the cancer cell and other antigen presenting cells. The definition of such peptides is a prerequisite for development of cancer vaccines and cancer therapy based on T cell immunity.

#### Technical Background

The genetic background for the onset of cancer are proto-oncogenes and oncogenes. Proto-oncogenes are normal genes of

the cell which have the potential of becoming oncogenes. All oncogenes code for and function through a protein. In the majority of cases they have been shown to be components of signal transduction pathways. Oncogenes arise in nature from proto-oncogenes through point mutations or translocations, thereby resulting in a transformed state of the cell harbouring the mutation. Cancer develops through a multistep process involving several mutational events and oncogenes.

In its simplest form a single base substitution in a proto-oncogene may cause the resulting gene product to differ in one amino acid.

In experimental models involving murine tumours it has been shown that point mutations in intracellular "self"-proteins may give rise to tumour rejection antigens, consisting of peptides differing in a single amino acid from the normal peptide. The T cells recognizing these peptides in the context of the major histocompatibility (MHC) molecules on the surface of the tumour cells are capable of killing the tumour cells and thus rejecting the tumour from the host. (Boon, T. et al, Cell, 1989, Vol. 58, p 293-303)

In the field of human cancer immunology the last two decades has seen intensive efforts to characterize genuine cancer specific antigens.

In particular, effort has been devoted to the analyses of antibodies to human tumour antigens. The prior art suggests that such antibodies could be used both for diagnostic and therapeutical purposes, for instance in connection with an anti-cancer agent. One problem is that antibodies can only bind to tumour antigens that are exposed on the surface of tumour cells. For this reason the efforts to produce a cancer treatment based on the immune system of the body has been less successful than expected.

Antibodies typically recognize free antigen in native conformation and can potentially recognize almost any site exposed on the antigen surface. In contrast to the antibodies produced by the B cells, T cells recognize antigens only in the context of MHC molecules, designated HLA (human leucocyte antigen) in humans, and only after appropriate antigen processing, usually consisting of proteolytic fragmentation of the protein, resulting in peptides that fit into the groove of the MHC molecules. This enables T cells to recognize also peptides derived from intracellular proteins. T cells can thus recognize aberrant peptides derived from anywhere in the tumor cell, in the context of MHC molecules on the surface of the tumor cell, and subsequently can be activated to eliminate the tumor cell harbouring the aberrant peptide.

The HLA molecules are encoded by the HLA region on the human chromosome No 6. The class I molecules are encoded by the HLA A, B and C subloci, and the class II molecules are encoded by the DR, DP and DQ subloci. All the gene products are highly polymorphic. Different individuals thus express distinct HLA molecules that differ from those of other individuals. This is the basis for the difficulties in finding HLA matched organ donors in transplantations. The significance of the genetic variation of the HLA molecules in immunobiology is reflected by their role as immune-response genes. Through their peptide binding capacity, the presence or absence of certain HLA molecules governs the capacity of an individual to respond to peptide epitopes. As a consequence, HLA molecules determine resistance or susceptibility to disease.

T cells may control the development and growth of cancer by a variety of mechanisms. Cytotoxic T cells, both HLA class I restricted CD8+ and HLA Class II restricted CD4+, may directly kill tumour cells carrying the appropriate tumour antigens. CD4+ helper T cells are needed for cytotoxic T cell

responses as well as for antibody responses, and for inducing macrophage and LAK cell killing.

Although the prior art has identified many oncogenes and their protein products, and a recently published study has shown that the T cell repertoire of a healthy person includes T cells with a specificity against a synthetic peptide fragment derived from one p21 ras oncogene product, no previous studies have defined the correct antigens or antigenic sites giving rise to tumour specific T cell immunity.

Thus the present invention is based on the idea that another possible approach for combatting cancer is by using the body's own immune system through an activation and strengthening of the immune response from specific T cells.

#### Definition of the Invention

It has now according to the present invention been found synthetic peptides and peptide fragments of oncogene proteins which elicit specific T cell responses against cancer cells which harbour an oncogene.

The peptides and fragments according to this invention are characterized in that they

a) have a point of mutation or translocation as compared to the corresponding fragment of the proto-oncogene protein;

and

b) correspond to, completely cover or are a fragment of the processed oncogene prot in fragment as presented by the cancer cell or other antigen presenting cells (APC);



and

c) induce specific T cell responses to the actual oncogene protein fragment produced by the cell by processing and presented by the HLA molecule.

Since these mutations give rise to the transforming capacity of oncogenes, they are pivotal in the development of cancer. By raising specific T cell responses against these mutations control of the development and growth of the tumour cells carrying the mutation is possible. Thus for the first time it is possible to develop prophylaxis and therapy directed against the specific genetic alterations in neoplastic cells.

#### Detailed Description of the Invention

One purpose of the present invention is to develop a vaccine to prevent the establishment of cancers carrying the most commonly observed oncogene mutations, based partly or solely on synthetic peptides or peptide fragments of oncogene proteins which produce T cell immunity against the oncogene's gene product.

Another purpose of the present invention is to produce a cancer therapy for cancers having the said mutations in their proto-oncogenes, based on the T cell immunity which may be induced in patients by stimulating their T cell immunity either in vitro or in vivo with the peptides according to the present invention.

In order for a cancer vaccine and methods for specific cancer therapy based on specific T cell immunity to be effective, three conditions must be met:

1. The peptides used must correspond to, completely cover and/or be an active fragment of the processed oncogene protein fragment as presented by the cancer cell or other

antigen presenting cells,

2. The peptides used must be bound to a HLA molecule in an immunogenic form, and
3. T-cells capable of recognizing and responding to the HLA peptide complex must be present in the circulation of the subject.

It has been established that all these conditions are met for the peptides according to the present invention. The peptides according to the present invention give rise to specific T cell immune responses in vitro. The HLA molecules capable of binding each of the peptides were determined. Evidence for a general binding of ras peptides to DR and DQ molecules was further obtained in direct binding assays with purified DR and DQ molecules. It has been established that the synthetic peptides or peptide fragments according to this invention correspond to the processed oncogene protein fragments. This is exemplified with synthetic p21 ras peptide fragments having a mutation in position 61. Specific T cell memory responses were evoked in vitro by these synthetic peptides. This is a clear indication that the cancer patient's T cells had been activated by the same or very similar peptide fragments in vivo.

It has recently been established that the T cell repertoire of a healthy person encompass T cells with a specificity against a single synthetic peptide having a mutation in position 12, and it was further investigated if this phenomenon was of a general nature. Thus, a complete panel of peptides representing the known, common p21 ras mutations in the positions 12, 13 and 61 were tested looking for T cells being activated by these peptide fragments.

In the present description and claims, the amino acids are either represented by their full name or by the three letter abbreviation as known in the art.

Embodiments

The peptides according to this invention are synthetic peptides corresponding to and/or encompassing the processed peptide being presented by the cancer cell or other antigen presenting cells, including a mutation in one or more positions corresponding to the oncogene mutation, and giving rise to T cell immunity against the oncogene protein. The amino acid at the position of the point of mutation may be any amino acid except the amino acid found in the normal proto-oncogene encoded protein, but preferred are the amino acids found in oncogene proteins.

The peptides according to this invention further include fragments having one or several amino acid substitutions at the flanks of the point of mutation or translocation.

Transforming ras genes are the oncogenes most frequently identified in human cancer, with an overall incidence estimated to be around 10-20%. The transforming genes carry mutation in position 12, 13 and 61 in the ras gene product p21.

According to one aspect of this invention, the synthetic peptides are fragments including at least one of the positions 12, 13 and 61 of the oncogene protein ras p21, having the same amino acid sequence.

The amino acid in the position 12 may be any amino acid except Gly, which is found in the protein product encoded for by the proto-oncogene, when the remainder of the sequence corresponds to the normal proto-oncogene. One group of preferred peptides according to this invention are the peptides p113 - p119, the amino acid sequences of which will appear from Table 8, or fragments thereof, which will elicit a T cell response against the oncogene's protein product.

The amino acid in the position 13 may be any amino acid

except Gly, which is found in the protein product encoded for by the proto-oncogene. One group of preferred peptides according to this invention are the peptides p120 - p121, the amino acid sequences of which will appear from Table 8, or fragments thereof, which will elicit a T cell response against the oncogene's protein product.

The amino acid in the position 61 may be any amino acid except Gln, which is found in the protein product encoded for by the proto-oncogene. One group of preferred peptides according to this invention are the peptides shown in Table 9, or fragments thereof, which will elicit a T cell response against the oncogene's protein product.

Preferred peptides according to this invention are peptides or fragments of p21 ras proteins which are selected from the amino acids 1-25 and which have at least one mutation in the positions 12 and/or 13. The sequence of the amino acids 1-25 of the normal p21 ras protein having a Gly in both position 12 and 13 will appear from Table 6.

Other preferred peptides according to this invention are peptides or fragments of p21 ras proteins which are selected from the amino acids 45-72, especially 51-67 and which have at least one mutation in position 61. The sequence of the amino acids 45-72 of the normal p21 ras protein having a Gln in position 61 will appear from Table 6.

Other peptides according to the present invention are peptide fragments of p53 comprising at least mutations in position 273, in which position any amino acid except Arg may be located.

Further peptides according to the present invention are peptide fragments of the bcr-abl fusion proteins p210 and p190, in which exon 3 of bcr and exon 2 of abl are joined or fusion protein p210, in which exon 2 of bcr and exon 2 of abl

are joined.

Other peptides are peptide fragments of a bcr-abl fusion protein, where exon c3 of bcr and exon 2 of abl are joined.

Preferred peptides of this group will comprise the following fragments or parts thereof:

Ile-Pro-Leu-Thr-Ile-Asn-Lys-Glu-Glu-Ala-Leu-Gln-Arg-Pro-Val-Ala-Ser-Asp-Phe-Glu

Ala-Thr-Gly-Phe-Lys-Gln-Ser-Ser-Lys-Ala-Leu-Gln-Arg-Pro-Val-Ala-Ser-Asp-Phe-Glu

Ala-Phe-Asp-Val-Lys-Ala-Leu-Gln-Arg-Pro-Val-Ala-Ser-Asp-Phe-Glu

Still other preferred peptides are fragments of ret fusion protein, comprising the following sequence or parts thereof: Leu-Arg-Lys-Ala-Ser-Val-Thr-Ile-Glu-Asp-Pro-Lys-Trp-Glu-Phe

Still other preferred peptides are fragments of the EGF receptor fusion protein comprising the following sequence or parts thereof: Ser-Arg-Ala-Leu-Glu-Glu-Lys-Lys-Gly-Asn?-Tyr-Val-Val-Thr-Asp-His-Gly

Still other preferred peptides are fragments of the retinol receptor fusion protein comprising the following sequence or parts thereof: Leu-Ser-Ser-Cys-Ile-Thr-Gln-Gly-Lys-Ala-Ile-Glu-Thr-Gln-Ser-Ser-Ser-Ser-Glu-Glu

The present invention further includes larger fragments carrying a few amino acid substitutions at either the N-terminal or the C-terminal end, as it has been established that such peptides may give rise to T cell clones having the appropriate specificity.

The peptides or fragments according to the present invention may be symmetrical or unsymmetrical around the position where the mutation is found in the oncogene proteins.

Further it is considered that the peptides may be administered together, either simultaneously or separately, with compounds such as cytokines, i.e. interleukin-2 or the like in order to strengthen the immuneresponse as known in the art.

The invention includes, but is not limited to these specific peptides and any synthetic peptides containing or overlapping these sequences or variations therein, including peptides with amino acid substitutions that retain or enhance the activity documented.

The peptides according to the present invention can be used in a vaccine or a therapeutical composition either alone or in combination with other materials, such as for instance in the form of a lipopeptide conjugate which as known in the art may induce high-affinity cytotoxic T lymphocytes, (K. Deres, Nature, Vol.342, (nov.1989)).

The peptides or peptide fragments according to the present invention may be useful to include in either a synthetic peptide or recombinant fragment based vaccine.

The peptides of the present invention are particularly suited for use in a vaccine capable of safely eliciting either type of immunity:

- (1) the peptides are synthetically produced and therefore do not include transforming cancer genes or other sites or materials which might produce deleterious effects,
- (2) the peptides may be used alone to induce cellular

immunity,

- (3) the peptides may be targeted for a particular type of T cell response without the side effects of other unwanted responses.

The peptides or fragments according to the present invention can be included in pharmaceutical compositions or in vaccines together with usual additives, diluents, stabilizers or the like as known in the art.

According to this invention, a pharmaceutical composition or vaccine may include the peptides or fragments alone or in combination with at least one pharmaceutically acceptable carrier or diluent.

Further a vaccine composition can comprise a selection of peptides having the most common mutations as found in oncogene proteins.

Further a vaccine composition can comprise a peptide selected for one cancer, which vaccine would be administered to persons belonging to a high risk group for this particular cancer.

The peptides and peptide fragments according to this invention may be produced by conventional processes as known in the art, and this is elucidated in the description of the synthesis below.

As mentioned above a cancer vaccine according to the present invention may be administered to persons belonging to a high risk group for one definite cancer connected to one or several oncogenes. Examples of oncogenes found in human tumours will appear from Table 5.

The cancer vaccine according to this invention may further be

administered to the population in general for example as a mixture of peptides giving rise to T cell immunity against various common cancers.

A cancer therapy according to the present invention may be administered both in vivo or in vitro having as the main goal the raising of specific T cell lines or clones against the gene product of the oncogene responsible for the cancer type with which the patient is afflicted.

#### BIOLOGICAL EXPERIMENTS

##### Description of the Figures

Figure 1 shows the protocol for eliciting p21 ras peptide specific T cell responses in normal donors in vitro, and for cloning of such cells. Mononuclear cells from peripheral blood (PBMC) were isolated from defibrinated blood by centrifugation on Lymphoprep (Nycomed, Oslo, Norway). Washed PBMC were resuspended in RPMI 1640 (Gibco, Paisley, Scotland) supplemented with 100 IU/ml penicillin, streptomycin (100 µg/ml) and 15 % autologous serum, and the indicated amounts of synthetic peptides and incubated in a 5 % CO<sub>2</sub> incubator at 37°C. The structure of the peptides used is given in Table 1. All of the peptides representing mutations i position 12 and 13 contains an additional alanine or valine in the C-terminus.

For the T cell cloning procedure, T cell blasts were seeded at 1 or 10 blasts per well in Terasaki plates in the same peptide containing medium as above. Each well contained 25000 irradiated (2000R) autologous PBMC as feeder cells and was supplemented with recombinant human IL-2 (Amersham, England) at a final concentration of 20 U/ml, in a total volume of 20 µl. T cell growth was evaluated microscopically on day 5-6 and transferred to 96 well plates (Costar, Cambridge, Ma, USA). Each well contained 100000 fresh, irradiated autologous



PBMC as feeder cells, as well as peptides and IL-2 as above, in a final volume of 120  $\mu$ l microlitre. Growing clones were further expanded in 24 well plates on day 3-5 after transfer from 96 well plates, in the same manner as described above, and restimulated weekly with fresh irradiated feeder cells, peptides and IL-2. Further expansion of the clones was done in medium containing only IL-2, and finally in medium without peptides or IL-2.

Figures 2a-2e show the specificity of the T cell clones I, B, E and F in T cell proliferation assays. Assays were set up in triplicate in 96 well plates, with the five peptides present in the original peptide mixture as stimulating antigens. The wells contained 50000 irradiated (8000 R) autologous EBV transformed B cells as antigen presenting cells (APC).

Cultures were incubated for 2 days at 37 °C in a 5 % CO<sub>2</sub> incubator, and pulsed overnight with 1  $\mu$ Ci of <sup>3</sup>H-thymidine (Amersham, England) per well before harvesting onto glass fibre filters by an automated cell harvester (Scatron, Lierbyen, Norway). Thymidine incorporation into DNA was quantitated by liquid scintillation counting using an LKB 1205 Betaplate Liquid Scintillation counter. Data are given as medians of triplicate cultures. Controls included T cell clones cultured alone, or with APC in the absence of peptides. The panels are scaled according to the magnitude of the positive response.

Figure 3a-3d show the results of blocking experiments with clones I, B, E and F using the monoclonal antibodies L243, specific for HLA-DR and FN81.1.1, specific for HLA-DQ. Proliferation assays were as described in Figure 2, with the exception that the APC were preincubated for 30 minutes at 37 °C with the indicated concentration of monoclonal antibody before the addition of T cells and peptides to the incubation mixture. Data are expressed as described in Figure 2.

Figure 4 shows peptide inhibition studies with clone I as indicator responder cell. Conditions were as described in Figure 2, except that 10  $\mu$ molar concentration of stimulatory peptide (peptide 42) and 250  $\mu$ molar concentration of the inhibitory peptides were used. APC were preincubated for 30 minutes at 37 °C with inhibitory peptides before the addition of stimulatory peptides and T cells. Data are expressed as in Figure 2. (Note: peptide 42 at a concentration of 250  $\mu$ molar appears to inhibit clone I. This is also evident from the dose response curve of this clone with peptide 42 (data not shown).)

Figure 5 shows similar results as in Figure 4, this time inhibition of the response of clone E to peptide 43 is recorded. Conditions are otherwise as described in Figure 4.

Figure 6 shows the response of clone E to truncated forms of peptide 43. The peptides were truncated from the N-terminal and C-terminal end as seen in Table 2. The conditions of the assay were as described in Figure 2. Each peptide was present in a concentration of 10  $\mu$ molar, and the number of responder T cells and APC was 50000.

Figure 7 shows peptide inhibition studies with clone E as indicator responder cell, and using the same truncated forms of peptide 43. Five  $\mu$ molar concentration of stimulatory peptide (peptide 43) and 250  $\mu$ molar of the inhibitory peptides were used. Conditions were otherwise as described in Figure 4. Note: Peptide 65 and 81 are non-stimulatory in a concentration of 10  $\mu$ molar (fig. 6), but are stimulatory in a concentration of 250  $\mu$ molar.

Figure 8 shows the response of clone F to truncated forms of peptide 45. The structure of the peptides is given in Table 2. The conditions of the assay were exactly as described in Figure 6.

Figure 9 shows the results of stimulation of PBMC from a patient with follicular thyroid carcinoma with the whole panel of p21 ras derived peptides. PBMC, 100000 cells/well in 96 well plates were incubated with 100 µg/ml of each peptide in the absence of (first column) or presence of (second column) 1 U/ml of recombinant human IL-2. <sup>3</sup>H-thymidine (1 µCi) was added on day 6, and the cultures harvested and processed on day 7 as described in Figure 2. Results are given as medians of triplicates. Controls were PBMC cultured alone or in the presence of recombinant IL-2.

Figure 10 shows the response of PBMC from the same donor as in Figure 9 to peptide 23, in the presence or absence of IL-2. Conditions are as in Figure 9, except that 200000 cells per well was used, as well as two different doses of peptide.

Figure 11 shows the response of a secondary T cell culture derived from the patient described in Figure 9 and 10 to five peptides representing the amino acid sequence around position 61 of the normal and mutated p21 ras proteins.

Conditions were as described in Figure 2, except that 25000 of the responder cells and APC were used, and the peptide concentration was 200 µg/ml.

Figure 12 shows the reactivity of the T cell clones 10, 14, 15, and 23 towards peptide 23. Conditions of the assay were as described in Figure 2, except that 50000 irradiated allogeneic HLA-DQ identical PBMC were used as APC, and peptide concentration was 50 µg/ml.

Figure 13 shows the results of blocking experiments with clone 14, using a monoclonal antibody FN81.1.1., specific for HLA-DQ. Conditions were as described in Figure 2 and 3.

Figure 14 shows the response of clone 15 to truncated forms of peptide 23. The peptides were truncated from the N-

terminal and C-terminal end as seen in Table 7. The conditions of this assay were as described in Figure 2, with the exception that each peptide was used in final concentration of 20, 50 and 100  $\mu$ molar. The number of responder cells and APC was 50 000.

Figure 15 shows the response of clone 14 to a new set of synthetic peptides carrying the same mutation in position 61 as found in peptide 23. These new peptides encompass the sequences 51-67, 52-67, 53-67, 51-65, 52-65 and 53-65 of the ras sequence, see Table 6. The sequences of these peptides are given in Table 7. Conditions were as described in Figure 14.

Figure 16 shows dose-response curves for clone F to peptide 45, and peptides 88-91. The structures of the peptides are given in Table 2. The peptide concentration was as given in the Figure, and the conditions of the assay were otherwise as described for Figure 6.

Figure 17 shows the response of clone B to truncated forms of peptide 43 and of clone I to truncated forms of peptide 42. The peptides were truncated from the N-terminal and C-terminal end as seen in Table 2. For each peptide three different doses were used, the final concentrations being 20, 50 and 100  $\mu$ molar. The number of responder cells and APC was 50 000. The conditions of the assay were as described in Figure 2.

Figures 18a - 18d show the result of experiments where clones B, I, E and F were stimulated with a panel of long peptides. For each peptide three different doses were used, the final concentrations being 20, 50 and 100  $\mu$ molar. For comparison the clones were stimulated with peptides 42, 43, 44 and 45 used for eliciting the clones. The number of responding cells and APC were 50 000. Conditions were otherwise as described for Figure 2.

Figure 19 shows the response of two T cell clones KB 15 and KB 23 derived from a healthy donor after repeated stimulation with a mixture of long peptides, (p-112, p-113, p-114, p-115 and p-116) ) Culture conditions were essentially as described in Figure 1.

Figure 20 shows the results of growth inhibition studies of IFN- $\gamma$  treated HT29 colon carcinoma cells (ATCC, Rockville MD) using clone 14 as effector cells. The number of target cells seeded per microwell was 20 000, and the cells were treated with recombinant human IFN (Amersham, UK), 500 U/ml for 3 days before the addition of irradiated (2000 rad) effector cells as indicated in the Figure. Peptide treated cells were cultured for the last 24 hours with peptide 106 at the final concentration of 10  $\mu$ g/ml. After addition of effector cells, cultures were pulsed overnight with 1  $\mu$ Ci of  $^3$ H-Thymidine per well before harvesting as described in Figure 2. Specific growth inhibition was calculated from incorporation data of control cultures without peptide added.

Induction of ras specific T cells by primary immunization in vitro.

We first investigated if the T cell repertoire of normal healthy persons contained T cells capable of recognizing and responding to a panel of peptides carrying amino acid sequences derived from mutated p21 ras.

Peripheral blood mononuclear cells from healthy donors were stimulated in vitro with mixtures of synthetic p21 ras peptides according to the present invention as described in Figure 1.

The results of some of these experiments are shown in Table 3. No primary response against the peptide mixtures could be observed. Similar experiments with a panel of 15 healthy donors stimulated with individual peptides also demonstrated a complete lack of primary responses against these peptides

(data not shown). Together these results indicate that the frequency of responsive cells in a normal population is very low. However, when in vitro cultures were repeatedly stimulated with peptides and fresh irradiated antigen presenting cells, strong response against the corresponding peptides could be observed (Table 3).

These data clearly demonstrate that after appropriate in vitro immunization with peptides carrying amino acid sequences derived from mutated oncogenes, specific T cell responses can be obtained. Thus we also have shown that T cells with specificity for p21 ras derived peptides are present in a normal T cell repertoire, and this donor has HLA molecules that are capable of binding such peptides.

We next wanted to investigate the fine specificity of the T cells capable of recognizing p21 ras peptides and to define the HLA molecules that are responsible for binding of these peptides and presenting them to the responding T cells. To this end we cloned the activated T cells present in the culture which was responding to a mixture containing the peptides P-42 to P-46. The cloning procedure is described in Figure 1. Data from the cloning experiments are summarized in Table 4. Of the clones showing specificity for single peptide, four were selected for further studies.

Clone I showed exclusive specificity for peptide 42 which contains the amino acid lysine in position 12. Substituting lysine with several other amino acids totally abrogated the response (Figure 2a).

The response against peptide 42 could be completely blocked with the reference monoclonal antibody against HLA-DR, L243, but not with monoclonal antibodies against HLA-DQ and -DP, demonstrating that peptide 42 is bound to HLA-DR in this particular donor (Figure 3a).

Clone B showed exclusive specificity for peptide 44 which contains the amino acid arginine in position 12. None of the other peptides were recognized (Figure 2b).

As with clone I, clone B was also HLA-DR restricted as evidenced by blocking studies with monoclonal antibodies (Figure 3b).

Clone E showed exclusive specificity for peptide 43 which contains the amino acid valine in position 13. None of the other peptides were recognized (Figure 2c).

Contrary to the clones recognizing peptide 42 and peptide 44 this clone was not blocked by anti HLA-DR monoclonal antibodies, but instead was blocked by a monoclonal antibody recognizing HLA-DQ (Figure 3c). Anti HLA-DP had no effect. These data show that peptide 43 is bound to HLA-DQ in this particular donor.

Clone F showed a different pattern of reactivity. Clone F gave very strong responses against peptide 45 containing alanine in position 12, which was present in the original peptide mixture. It was unreactive to the other peptides in the mixture (Figure 2d), but reacted to a variable degree towards the other peptides (Figure 2e). The reactivity of this clone seemed to be critically dependent on having amino acid glycine in position 13 since substitution of this glycine with aspartic acid or valine totally abrogated the response. Substitution of glycine in position 12 with the basic amino acid lysine or arginine resulted in low or no responses indicating that such substitutions interfere with the T cell receptor binding site. As with clone E, this clone was also HLA-DQ restricted as demonstrated by blocking by monoclonal antibodies (Figure 3d). One interesting observation is that the two peptides carrying basic amino acids in position 12, and which fail to stimulate the HLA-DQ restricted clone F, both are capable of binding to HLA-DR and are

recipr cally recognized by the two clones I and B.

In order to map peptide binding to HLA-DR and HLA-DQ, we tested the non-stimulatory p21 ras peptides for capacity to inhibit the binding of peptide 42 to HLA-DR, using stimulation of clone I as indicator system, and inhibition of peptide 43 binding to HLA-DQ using stimulation of clone E as an indicator system.

Binding of peptide 42 to HLA-DR was strongly inhibited by a 25 fold excess of peptides 39, 40, 41, 43, 44 and 45 (Figure 4). The other peptides only marginally inhibited the binding. Notably, none of the peptides carrying amino acid 61 were able to significantly inhibit binding to HLA-DR and subsequent activation of clone I. Conversely, all of the peptides inhibited binding of peptide 45 to HLA-DQ, and subsequent activation of clone E (Figure 5). Thus, all the peptides carrying amino acid sequences derived from p21 ras, were capable of binding HLA-DQ, including the peptides carrying the unmutated 6-19 sequence (gly in position 12 and 13) and the unmutated 54 to 69 sequence (gln in position 61). It is thus possible that all of these peptides may be immunogenic in the context of HLA-DQ, and that several of the peptides in addition may be immunogeneic in the context of HLA-DR, as already shown for peptide 42 and 44, and a peptide containing Val in position 12 (Jung & Schluesener, 1991).

In order to investigate which amino acids were essential for peptide recognition by the HLA-DQ restricted T cell clones E and F, we synthesized truncated forms of peptide 43 and 45 as shown i Table 2. The peptides were truncated both from the N-terminal and C-terminal end. The first important question was whether the addition of a duplication of amino acids Ala and Leu in the C-terminal part of the peptides used for in vitro immunization was of importance. Results in Figures 6 and 8 dem nstrat that the two additional amino acids contributed marginally to the site recognized by clone E, and were



of no importance for the recognition of peptide by clone F. Since peptide 79 lacking the duplicated amino acids was equally efficient in stimulating clone F. Peptides 64, 79 and 80 stimulate clone E in a concentration of 10 $\mu$ l. Peptide 65 and 81 become stimulatory in a concentration of 250 $\mu$ l. Peptides 66, 67, 68, 82 and 83 inhibit at this concentration (Figure 7), and are thus capable of binding to HLA-DQ. Peptides 69, 70, 74, 75 and 76 stimulate clone F at 10 $\mu$ l concentrations.

The combined data in Figure 6-8 show that several peptides carrying Ala in position 12 or Val in position 13 and varying in length, can be recognized by clones E and F. The striking symmetry in the results with clone E and F demonstrate that the amino acids Val in position 8 and Ser in position 17 are absolutely essential for stimulation of these T cell clones. A predicted minimum peptide for stimulation of clone E will therefore have the sequence Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser and for Clone F the sequence Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser. The predicted minimum peptide 8-17, 12-Ala, (peptide 88) was synthesized and its capacity to stimulate clone F was compared to peptide 45 and several other peptides as depicted in Figure 16. The dose-response curve for peptide 88 confirms its stimulatory capacity, but shows that it is far less potent than the peptide used for eliciting this clone. Shorter peptides still bind HLA-DQ, but have lost amino acids critical for recognition by these T cell clones. We anticipate that also these peptides, when used to stimulate T cells in vitro, may give rise to a new set of T cell clones with slightly different specificities.

In order to investigate if the same amino acids that were identified as being important for peptide recognition by the HLA-DQ restricted T cell clones were also essential for the recognition by the DR restricted clones B and I, we synthesized truncated forms of the peptides 42 and 44 as shown in Table 2. The peptides were truncated both from the

C- and N-terminal ends. Results in Figure 17 confirms that the duplicated amino acids Ala and Leu were of no importance for recognition by these T cell clones. For both clones, Lys in position 16 is absolutely essential as removal of this amino acid abrogates the peptide response. The two clones differ in their requirement for the presence of Val in position 7, as this amino acid is essential for stimulation of clone B, while its presence seems to negatively influence the response to clone I. From the results in Figure 17 the minimum peptides for stimulation of clone B and I are Val-Val-Val-Gly-Ala-Arg-Gly-Val-Gly-Lys and Val-Val-Gly-Ala-Lys-Gly-Val-Gly-Lys.

To address the question of peptide processing, we synthesized p21 ras peptides encompassing the residues 1-25. Presumably these peptides would allow the generation of naturally processed peptides when fed to the APC. The results of this series of experiments are given in Figure 18. All the clones were able to respond to the 1-25 peptides provided the correct amino acid substitution in positions 12 and 13 were present. When compared to the response against the peptides used in primary stimulation, long peptides were more efficient in stimulating clones B and F. Clones E and I showed the opposite reactivity pattern. These results may indicate that processing of the long peptides may give rise to peptides which differ from the peptides used for generation of the clones.

To summarize the results obtained with only four of our T cell clones:

1. Peptides 45, 41, 40, 39, ( and 37) and peptide 43 can be recognized by T cell clones F and E respectively. Peptides 42 and 44 are recognized by clones I and B respectively, thus all but two of the most common p21 Gly-12 and Gly-13 ras mutations can be recognized by a limited set of T cell clones derived from precursor T cells present in the normal repertoire of a single donor.

2. Peptides can bind to both HLA-DR and DQ molecules, since peptides are recognized in a HLA-DR restricted manner (Clone I and B) and in a HLA-DQ restricted manner (clone E and F).
3. By using truncated peptides we have defined putative minimum sequences required for stimulation of our DQ and DR restricted T cell clones. All clones require the presence of a core sequence spanning positions 8-16 and differ only slightly in the requirements of amino acids in the positions flanking this sequence.
4. Both the DQ and DR restricted clones can respond to peptides of varying length, from the short core sequence up to sequences of 25 amino acids.
5. Our T cell clones have also provided us with important insight into those peptides where no reactive clones are available. Thus, by blocking experiments using 25-50 fold excess of peptides, and the clones E, F, and I as indicator responder cells, we have demonstrated as shown in Figure 5 that all the synthetic peptides in this study, including the peptides representing ras mutations in amino acid 61, are capable of binding to HLA-DQ, and that several of the peptides are capable of binding to HLA-DR.

Having achieved responses in healthy donors by primary immunization in vitro with the shorter peptides, (peptides 42, 43, 44, 45), and observed that T cell clones elicited by stimulation with these peptides were capable of responding to the longer peptides, which presumably required processing, we investigated if the long peptides also would elicit T cell responses after primary stimulation. For these experiments we selected normal donors having HLA molecules not previously known to bind ras peptides. The results from these experiments appear in Figure 19. Peptides 114 and 115 were capable of stimulating specific T cell responses, and T cell clones recognizing these peptides could be generated from bulk cultures. Thus peptides spanning the sequence 1-25 and containing amino acid substitutions in position 12 are also immunogenic. Our results also show that ras peptide

responsiveness is not confined to a single HLA haplotype.

In order to investigate the general nature of ras peptide binding to HLA molecules, we established a binding assay for measuring peptide binding to purified HLA DR and DQ molecules. To compare the binding of ras peptides with a standard, high affinity binding peptide, we first studied inhibition of a radio labelled influenza matrix peptide to purified HLA DR1 molecules. Results shown in Table 11 demonstrate that all the peptides tested were capable of binding to DR1. The binding strength of the ras peptides, as measured by the capacity to inhibit binding of the indicator peptide, was similar to that of the influenza matrix peptide. These data confirm the binding capacity of the peptides used for T cell stimulation, and also demonstrate that non-stimulatory peptides can bind to HLA DR. Furthermore, these data extend our knowledge of DR molecules capable of binding ras peptides to include also DR1. The observation on peptide binding to purified DQ molecules confirms our cellular studies and provides a first example on direct binding of peptides to purified DQ molecules.

The observation so far indicate that binding of ras derived peptides may be a general phenomenon, perhaps reflecting an important surveillance function of the HLA / T cell system in eliminating cells carrying potentially deleterious ras mutations.

It should be noted that our T cell responses are obtained without the addition of exogenous IL-2 to the cell cultures, and thus depend on the inherent capacity of our synthetic peptides to induce specific proliferative responses in the donor T cells. This offers a great advantage over recent techniques based on massive use of IL-2 to induce in vitro proliferation of cells from cancer patients, either derived from peripheral blood (LAK cells) or from tumour infiltrating lymphocytes (TIL cells). This nonspecific manner of T (and

NK) cell activation is responsible for the severe side effects seen in patients given treatment with LAK or TIL cell preparations.

The new finding that the T cell repertoire of a normal individual contain T cells capable of specifically recognizing peptides containing several of the mutations commonly found in ras oncogenes in human cancers, is of importance in cancer therapy and the prevention of cancer by prophylactic vaccination. Furthermore it is also important that all of the synthetic peptides from ras oncogenes are capable of binding to HLA gene products as demonstrated in the peptide blocking experiments.

Of central importance is the finding as shown below, that peripheral blood from a patient with follicular carcinoma of the thyroid gland contain lymphocytes capable of giving a classical memory response against a ras p21 synthetic peptide representing one of the ras mutations commonly found in this cancer form. Such a response is not to be expected unless the patient's T cells have experienced a prior exposure to the same or a very similar peptide fragment in vivo. Such exposure is easily envisaged to occur if the cancer cell of the patient harbour this specific mutation of amino acid 61.

#### Demonstration of ras peptide specific memory T cells in cancer patients

The synthetic peptides employed for induction of ras peptide specific T cells by primary immunization in vitro, were constructed without precise knowledge of the composition of naturally occurring ras peptides formed by processing of the mutated ras gene product by proteolytic enzymes in vivo.

Although we have demonstrated that each clone shows sr

city for individual peptides r presenting different mutati n of otherwise identical peptides from ras, indicating that the amino acid representing the mutation forms an essential part of the site recognized by the T cell and that each clone may recognize several peptides of different length derived from the same mutated product, one crucial point remains to be elucidated. In order to retain functional competence in vivo (i.e. for prophylactic and therapeutic purposes), T cells/ clones derived by specific stimulation by synthetic peptides must overlap in their specificity with peptides derived from the cancer cells.

We accordingly tested PBMC from several cancer patients that had tumours where high incidences of ras mutations have been reported, for evidence of previous recognition of ras derived peptides (i.e. memory T cell responses). Of several patients showing evidence of prior T cell stimulation, one was selected for further studies. Results recorded in Figure 9 show that a patient with a follicular thyroid carcinoma was capable of responding to peptide 23. Response was synergistically enhanced by the addition of recombinant human IL-2. The response was confirmed in a second experiment (Figure 10), using higher number of cells and a higher concentration of peptide 23. One week after stimulation with peptide 23, the culture was restimulated, this time with five different peptides derived from ras around amino acid 61. Only peptide 23 was capable of restimulating the cells, demonstrating exclusive specificity for this peptide (Figure 11). T cell clones from the patients were established by cloning from bulk culture on day 3 of restimulation using the protocol outlined in Figure 1. Several hundred T cell clones were obtained, and the results of four of these clones are shown in Figure 12. Clone 10, 14, 15 and 23 all respond strongly to peptide 23. The clones are HLA-DQ restricted (inhibition with mAb FN 81.1.1, Figure 13 and data not shown), as predicted from our peptide blocking experiments with peptide 23 using the DQ restricted clone E (Figure 7). The capacity of peptide

23 to elicit a strong T cell response in a cancer patient, in a classical memory T cell assay, strongly suggests that the T cells have encountered an identical or very similar peptide in vivo.

In order to further investigate this, we synthesized a series of truncated forms of the peptide 23, and tested their capacity to stimulate clone 15. Data given in Figure 14 show that the N terminal amino acids Asp in position 54 and Ile in position 55 are critical for recognition by clone 15. Removal of Asp 54 strongly reduces the response, and removal of Ile 55 totally abrogates the response. As shown in figure 14, clone 15 was insensitive to the removal of the C terminal amino acids Asp 69, Arg 68, Met 67 and Ala 66. Removal of Ser 65 strongly reduced the response. Together these data indicate that the processed p21 ras peptide which originally stimulated these T cells in vivo may have contained additional amino acids from the N terminal sequence of the ras protein. We accordingly synthesized new peptides that lacked several of the C terminal amino acids that were found not to contribute to T cell recognition, but contained the new amino acids Leu 53, Leu 52 and Cys 51, derived from the natural p21 ras sequence. Data showing stimulation of clone 14 with this set of peptides are given in Figure 15. Optimal stimulation was seen with peptide 106 which encompasses the sequence 51-67. The observation that an even stronger response is achieved with a peptide having a sequence which differs significantly from the peptide used for in vitro stimulation of the T cell giving rise to the clone, strongly indicates that peptide 106 is more representative of the peptide processed by the cancer cell and originally giving rise to an immune response than peptide 23.

It is noteworthy that the cancer type of the patient is the only where high incidences of ras mutations in position 61 have been reported.

Thus it is shown that the processing of the mutated ras proteins in vivo must result in peptides very similar or even identical to the synthetic peptides according to this invention. The use of synthetic peptides in order to enhance in vitro the pre-existing T cell response of cancer patients is thus highly feasible. Such in vitro expanded ras specific T cell populations may contribute to eradicating the tumour cells carrying ras mutations from the patient in a refined LAK/TIL cell approach.

With oncogene specific T cells from a cancer patient available to us, we next wanted to investigate the possible role of such cells in regulating the growth of cancer cells in vitro. We accordingly tested the effect of 61 Leu specific T cell clone 14 on the growth of the human colon carcinoma cell line HT29 in vitro. This cell line can be induced to express the same HLA DQ molecules on its cell surface, as found in the cancer patient following exposure to recombinant IFN- $\gamma$ . The results in Figure 20 show that the growth of IFN- $\gamma$  treated cancer cells preincubated with the oncogene peptide, peptide 106, is strongly inhibited by the presence of the T cell clone recognizing this peptide in the context of HLA-DQ. The inhibition was dependent on the number of the cells added to the culture and the peptide concentration used. Control cancer cells treated with IFN- $\gamma$  alone were not influenced by the presence of this clone. These functional studies further indicate the usefulness of the peptides according to the invention for use in cancer therapy.

#### Synthesis

The peptides were synthesized by using continuous flow solid phase peptide synthesis (Biolynx 4170 synthesizer, Pharmacia LKB). N- $\alpha$ -Fmoc-amino acids with appropriate side chain protection ( Ser(tBu), Thr(tBu), Lys(Boc), His(Trt), Arg(Pmc), Cys(Trt), Asp(O-tBu), Glu(O-tBu) ) were used. The Fmoc-amino acids were activated by TBTU prior to coupling. 20% piperidine in DMF was used for selective removal of Fmoc after each



coupling. D tachm nt from the resin and final removal of side chain protection was performed by 95% TFA (aq.). The peptides were purified and analysed by reversed phase (C18) HPLC (Shimadzu LC8A). Amino acid analysis was carried out using the PICO-Tag method (Waters Millipore Inc.).

The following peptides and peptide fragments were synthesized by this method:

A1). ras peptides of the following sequence having mutation points in position 12 or 13:

6	7	8	9	10	11	12	13	14	15	16	17	18	19
Leu	Val	Val	Val	Gly	Ala	Gly	Val	Val	Gly	Lys	Ser	Ala	Leu

Other synthesized peptides having the sequence 1-25 of the normal ras peptide, but carrying mutations in position 12 or 13 will appear from Table 8.

A2) ras peptides of the following sequence having mutation points in position 12 or 13 and additional amino acids at one end not belonging to the natural sequence of the ras proteins:

6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
Leu	Val	Val	Val	Gly	Ala	Gly	Gly	Val	Gly	Lys	Ser	Ala	Leu	Ala	Leu
Leu	Val	Val	Val	Gly	Ala	Asp	Gly	Val	Gly	Lys	Ser	Ala	Leu	Ala	Leu
Leu	Val	Val	Val	Gly	Ala	Val	Gly	Val	Gly	Lys	Ser	Ala	Leu	Ala	Leu
Leu	Val	Val	Val	Gly	Ala	Cys	Gly	Val	Gly	Lys	Ser	Ala	Leu	Ala	Leu
Leu	Val	Val	Val	Gly	Ala	Ser	Gly	Val	Gly	Lys	Ser	Ala	Leu	Ala	Leu
Leu	Val	Val	Val	Gly	Ala	Lys	Gly	Val	Gly	Lys	Ser	Ala	Leu	Ala	Leu
Leu	Val	Val	Val	Gly	Ala	Arg	Gly	Val	Gly	Lys	Ser	Ala	Leu	Ala	Leu
Leu	Val	Val	Val	Gly	Ala	Ala	Gly	Val	Gly	Lys	Ser	Ala	Leu	Ala	Leu
Leu	Val	Val	Val	Gly	Ala	Gly	Val	Val	Gly	Lys	Ser	Ala	Leu	Ala	Leu
Leu	Val	Val	Val	Gly	Ala	Gly	Asp	Val	Gly	Lys	Ser	Ala	Leu	Ala	Leu

A3) ras peptides of the following sequence having mutation points in position 12 or 13 and having truncated N-terminal or C-terminal ends:

6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala														
Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala														
Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser														
Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser														
Leu-Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala														
Leu-Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser														
Leu-Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys														
Leu-Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly														
Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu														
Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu														
Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu														
Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu														
Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu														
Leu-Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala														
Leu-Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser														
Leu-Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys														
Leu-Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly														
Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu														
Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu														
Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu														
Ala-Gly-Val-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu														

B). ras peptides with a mutation in position 61:

54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69
Asp-Ile-Leu-Asp-Thr-Ala-Gly-Leu-Glu-Glu-Tyr-Ser-Ala-Met-Arg-Asp															
Asp-Ile-Leu-Asp-Thr-Ala-Gly-Arg-Glu-Glu-Tyr-Ser-Ala-Met-Arg-Asp															
Asp-Ile-Leu-Asp-Thr-Ala-Gly-Lys-Glu-Glu-Tyr-Ser-Ala-Met-Arg-Asp															
Asp-Ile-Leu-Asp-Thr-Ala-Gly-His-Glu-Glu-Tyr-Ser-Ala-Met-Arg-Asp															

c). abl-bcr fusion gene peptide:

Ile-Pro-Leu-Thr-Ile-Asn-Lys-Glu-Glu-Ala-Leu-Gln-  
Arg-Pro-Val-Ala-Ser-Asp-Phe-Glu

Ala-Thr-Gly-Phe-Lys-Gln-Ser-Ser-Lys-Ala-Leu-Gln-  
Arg-Pro-Val-Ala-Ser-Asp-Phe-Glu

d). egf receptor peptide and retinoid receptor peptide

Ser-Arg-Ala-Leu-Glu-Glu-Lys-Lys-Gly-Asn-Tyr-Val-  
Val-Thr-Asp-His-Gly

Leu-Ser-Ser-Cys-Ile-Thr-Gln-Gly-Lys-Ala-Ile-Glu-  
Thr-Gln-Ser-Ser-Ser-Ser-Glu-Glu

SYNTHETIC p21 ras PEPTIDES USED FOR IN VITRO T CELL STIMULATION.p21 Gly 12 mutations:

p37: Leu-Val-Val-Val-Gly-Ala-Gly-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu  
 p38: -----Asp-----  
 p39: -----Val-----  
 p40: -----Cys-----  
 p41: -----Ser-----  
 p42: -----Lys-----  
 p44: -----Arg-----  
 p45: -----Ala-----

p21 Gly 13 mutations:

p43: -----Gly-Val-----  
 p46: -----Asp-----

p21 Gln 61 mutations:

p22: Asp-Ile-Leu-Asp-Thr-Ala-Gly-Gln-Glu-Glu-Tyr-Ser-Ala-Met-Arg-Asp  
 p20: -----Arg-----  
 p21: -----Lys-----  
 p23: -----Leu-----  
 p24: -----His-----

p21 Leu 61 mutation:

p169: Leu-Asp-Ile-Leu-Asp-Thr-Ala-Gly-Leu-Glu-Glu-Phe-Gly-Ala-Met

Table 1

## TRUNCATED p21 ras PEPTIDES USED FOR IN VITRO T CELL PROLIFERATION ASSAYS

p45	Leu-Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p74	Leu-Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu
p75	Leu-Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala
p76	Leu-Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser
p77	Leu-Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys
p78	Leu-Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly
p69	-Val-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p70	-Val-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p71	-Val-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p72	-Gly-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p73	-Ala-Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p88	Val-Val-Gly-Ala-Gly-Val-Gly-Lys-Ser
p89	Val-Val-Val-Gly-Ala-Gly-Val-Gly-Lys-Ser
p90	Val-Val-Gly-Ala-Gly-Val-Gly-Lys-Ser-Ala
p91	Val-Val-Val-Gly-Ala-Gly-Val-Gly-Lys-Ser-Ala

p143	Leu-Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p179	Leu-Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala-Leu
p180	Leu-Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala
p181	Leu-Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser
p182	Leu-Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys
p183	Leu-Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly
p184	-Val-Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p185	-Val-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p186	-Val-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p187	-Gly-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p188	-Ala-Gly-Val-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p140	Leu-Val-Val-Val-Gly-Ala-Arg-Gly-Val-Gly-Lys-Ser-Ala
p141	Leu-Val-Val-Val-Gly-Ala-Arg-Gly-Val-Gly-Lys
p142	Leu-Val-Val-Val-Gly-Ala-Arg-Gly-Val-Gly-Lys-Ser
p143	Leu-Val-Val-Val-Gly-Ala-Lys-Gly-Val-Gly-Lys-Ser-Ala
p144	Leu-Val-Val-Val-Gly-Ala-Lys-Gly-Val-Gly-Lys-Ser
p145	Leu-Val-Val-Val-Gly-Ala-Lys-Gly-Val-Gly-Lys
p154	Val-Val-Val-Gly-Ala-Lys-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p155	Val-Val-Gly-Ala-Lys-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p156	Val-Val-Val-Gly-Ala-Arg-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p157	Val-Val-Gly-Ala-Arg-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu

p177	Leu-Val-Val-Val-Gly-Ala-Arg-Gly-Val-Gly
p178	Leu-Val-Val-Val-Gly-Ala-Arg-Gly-Val
p179	Leu-Val-Val-Val-Gly-Ala-Lys-Gly-Val-Gly
p180	Leu-Val-Val-Val-Gly-Ala-Lys-Gly-Val
p181	Val-Gly-Ala-Lys-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu
p182	Gly-Ala-Lys-Gly-Val-Gly-Lys-Ser-Ala-Leu-Ala-Leu

Table 2 cont.

TABLE 3

PRIMARY RESPONSE:	RESPONSE AFTER THE THIRD STIMULATION WITH PEPTIDE- MIXTURE III :	
	CPM	CPM
PBMC	9798,8	3686,1
PBMC+IL2	14060,7	29768,4
PBMC + PEPTIDE- MIXTURE III	9027,7	21706,9
PBMC + PEPTIDE- MIXTURE III + IL2	14365,0	44909,8

PBMC: 100000 cells per well  
 IL2: 1 U/ml final dilution  
 Peptidemixture III: 20 mikrogramms of each of the five peptides 42, 43, 44, 45, 46.



## The specificity of the clones:

---

16 out of 45 clones show specificity for the  
peptide mixture or a single peptide.

Peptide 42 2/45

Peptide 43 9/45

Peptide 44 1/45

Peptide 45 1/45

Peptide 46 0/45

Peptide mixture: 3/45

---

Table 5

EXAMPLES ON ONCOGENES AND TUMOR SUPPRESSOR GENES FOUND  
IN HUMAN TUMORS.

<u>proto-oncogene</u>	<u>neoplasm(s)</u>	<u>lesion</u>
abl	Chronic myelogenous leukemia	translocation
gip	Carcinoma of ovary and adrenal gland	point mutations
gsp	Adrenoma of pituitary gland; carcinoma of thyroid	point mutations
H-ras	Carcinoma of colon, lung and pancreas; melanoma	point mutations
K-ras	Acute myelogenous and lymphoblastic leukemia; carcinoma of thyroid; melanoma	point mutations
N-ras	Carcinoma of genito-urinary tract and thyroid; melanoma	point mutations
ret	Carcinoma of thyroid	rearrangement
trk	Carcinoma of thyroid	rearrangement

Tumor suppressor genes

rbl	Retinoblastoma; osteosarcoma; carcinoma of breast, bladder and lung	point mutation
p53	Astrocytoma; carcinoma of breast, colon and lung; osteosarcoma	point mutation

Table 6

THE SEQUENCE OF THE AMINO-ACIDS FROM POSITION 1 TO 26  
IN THE p21 h-, k- AND N-RAS PROTEIN:

Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-Gly-Gly-Val-  
Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-Leu-Ile-Gln-Asn

THE SEQUENCE OF THE AMINO-ACIDS FROM POSITION 45 TO 72  
IN THE p21 H-, K- AND N-RAS PROTEIN:

Val-Ile-Asp-Gly-Glu-Thr-Cys-Leu-Leu-Asp-Ile-Leu-Asp-Thr-  
Als-Gly-Gln-Glu-Glu-Tyr-Ser-Ala-Met-Arg-Asp-Gln-Tyr-Met

THE SEQUENCE OF THE AMINO-ACIDS FROM POSITION 53 TO 67  
IN THE p21 R-RAS PROTEIN:

Leu-Asp-Ile-Leu-Asp-Thr-Ala-Gly-Gln-Glu-Glu-Phe-Gly-  
Ala-Met

## TRUNCATED p21 ras PEPTIDES USED FOR IN VITRO T CELL PROLIFERATION ASSAYS:

p124:	Glu-Thr-Cys-Leu-Leu-Asp-Leu-Leu-Asp-Ile-Leu-Asp-Thr-Ala-Gly-Leu-Glu-Tyr-Ser-Ala-Met
p125:	Thr-Cys-Leu-Leu-Asp-Leu-Leu-Asp-Ile-Leu-Asp-Thr-Ala-Gly-Leu-Glu-Tyr-Ser-Ala-Met
p106:	Cys-Leu-Leu-Asp-Ile-Leu-Asp-Thr-Ala-Gly-Leu-Glu-Tyr-Ser-Ala-Met
p107:	Leu-----
p108:	Leu-----
p109:	Cys-Leu-Leu-Asp-Ile-Leu-Asp-Thr-Ala-Gly-Leu-Glu-Tyr-Ser
p110:	Leu-----
p111:	Leu-----
p188:	Asp-Ile-Leu-Asp-Thr-Ala-Gly-Glu-Tyr-Ser-Ala-Met
p 94:	Ile-Leu-Asp-Thr-Ala-Gly-Leu-Glu-Tyr-Ser-Ala-Met-Arg-Asp
p 95:	Leu-----
p 96:	Asp-----
p 97:	Thr-----
p 98:	Ala-----
p 99:	Asp-Ile-Leu-Asp-Thr-Ala-Gly-Leu-Glu-Tyr-Ser-Ala-Met-Arg
p100:	Asp-----Met
p101:	Asp-----Ala
p102:	Asp-----Ser
p103:	Asp-----Tyr

Table 7

Table 8

P 112:      1   2   3   4   5   6   7   8   9   10   11  
Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-  
12 13 14 15 16 17 18 19 20 21 22  
Gly-Gly-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-  
23 24 25  
Leu-Ile-Gln

P 113:      1   2   3   4   5   6   7   8   9   10   11  
Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-  
12 13 14 15 16 17 18 19 20 21 22  
Val-Gly-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-  
23 24 25  
Leu-Ile-Gln

P 114:      1   2   3   4   5   6   7   8   9   10   11  
Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-  
12 13 14 15 16 17 18 19 20 21 22  
Lys-Gly-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-  
23 24 25  
Leu-Ile-Gln

P 115:      1   2   3   4   5   6   7   8   9   10   11  
Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-  
12 13 14 15 16 17 18 19 20 21 22  
Arg-Gly-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-  
23 24 25  
Leu-Ile-Gln

P 116:      1   2   3   4   5   6   7   8   9   10   11  
Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-  
12 13 14 15 16 17 18 19 20 21 22  
Ala-Gly-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-  
23 24 25  
Leu-Ile-Gln

P 117:      1   2   3   4   5   6   7   8   9   10   11  
Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-  
12 13 14 15 16 17 18 19 20 21 22  
Ser-Gly-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-  
23 24 25  
Leu-Ile-Gln

Table 8 (Continued)

P 118:      1   2   3   4   5   6   7   8   9   10   11  
Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-  
12   13   14   15   16   17   18   19   20   21   22  
Cys-Gly-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-  
23   24   25  
Leu-Ile-Gln

P 119:      1   2   3   4   5   6   7   8   9   10   11  
Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-  
12   13   14   15   16   17   18   19   20   21   22  
Asp-Gly-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-  
23   24   25  
Leu-Ile-Gln

P 120:      1   2   3   4   5   6   7   8   9   10   11  
Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-  
12   13   14   15   16   17   18   19   20   21   22  
Gly-Val-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-  
23   24   25  
Leu-Ile-Gln

P 121:      1   2   3   4   5   6   7   8   9   10   11  
Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-  
12   13   14   15   16   17   18   19   20   21   22  
Gly-Asp-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-  
23   24   25  
Leu-Ile-Gln

Table 9

p158	Val-Ile-Asp-Gly-Glu-Thr-Cys-Leu-Leu-Asp-Ile- Leu-Asp-Thr-Ala-Gly-Leu-Glu-Glu-Tyr-Ser-Ala- Met-Arg-Asp-Gln-Tyr-Met
p166	Val-Ile-Asp-Gly-Glu-Thr-Cys-Leu-Leu-Asp-Ile- Leu-Asp-Thr-Ala-Gly-Arg-Glu-Glu-Tyr-Ser-Ala- Met-Arg-Asp-Gln-Tyr-Met
p168	Val-Ile-Asp-Gly-Glu-Thr-Cys-Leu-Leu-Asp-Ile- Leu-Asp-Thr-Ala-Gly-Lys-Glu-Glu-Tyr-Ser-Ala- Met-Arg-Asp-Gln-Tyr-Met
p167	Val-Ile-Asp-Gly-Glu-Thr-Cys-Leu-Leu-Asp-Ile- Leu-Asp-Thr-Ala-Gly-His-Glu-Glu-Tyr-Ser-Ala- Met-Arg-Asp-Gln-Tyr-Met

Clone:	Peptide specificity:	Response blocked by:
B	P-115	anti HLA-DR mAb
KB16	P-115	anti HLA-DQ mAb
KB11	P-115	anti HLA-DP mAb

Table 10



## BINDING OF PEPTIDES TO AFFINITY PURIFIED HLA MOLECULES

Peptides Sequences		Results	
		DQw6 IC50 ( $\mu$ M)	DR1 IC50 ( $\mu$ M)
P112	MTEYKLVVVVGAGGVGKSALTIQLIQ	6,02	1,21
P113	-----V-----	8,97	0,78
P114	-----K-----	2,53	0,55
P115	-----R-----	2,78	0,24
P116	-----A-----	2,68	0,44
P117	-----S-----	1,91	<0,11
P118	-----C-----	10	1,75
P119	-----D-----	3,03	1,10
P120	-----GV-----	7,31	0,74
P121	-----D-----	2,74	0,31
P88	VVGAAGVGKS	8,97	
P89	V-----	10	
P90	-----A	9,98	
P91	-----	1,29	
P45	L-----LAL	0,90	
P104	Y-----	<0,33	0,78
P34	SGPLKAEIAQLEY	>>10	0,15

Table 11

The binding of peptides to affinity purified HLA molecules was tested by their capacity to inhibit the binding of a radio-labeled indicator peptid. To test the binding of peptides to DQw6, iodinated P104 was used as an indicator peptide. Whereas iodinated P34 (derived from Influenza matrix protein aa 17-29) was used as indicator peptide to test the binding of peptides to DR1. In the table the concentration at 50 % inhibition (IC50) of the binding of the indicator peptide is shown. Low IC50 means good binding capacity. The peptides were tested in the concentration range from 0,33 - 10  $\mu$ M.

Table 11

Claims

1. A peptide characterized in that it

a) has a point of mutation or translocation as compared to the corresponding fragment of the proto-oncogene protein;

and

b) correspond to, completely cover or is a fragment of the processed oncogene protein fragment as presented by the cancer cell or other antigen presenting cells (APC);

and

c) induce specific T cell responses to the actual oncogene protein fragment produced by the cell by processing and presented in the HLA molecule.

2. A Peptide according to claim 1 characterized in that it has an amino acid sequence as the natural p21 ras protein except that the residue Gly in the positions 12 and/or 13 and/or Gln in position 61 are replaced by any other amino acid.

3. A Peptide according to claim 2 selected from the group consisting of A, B and C:

A) the peptides p113-p119 as appear from Table 8, or fragments thereof;

B) the peptides p120-p121 as appear from Table 8 or fragments thereof;

C) the peptides p158, p166, p168 and p167 as appear from Table 9 or fragments thereof.

4. A Pharmaceutical composition comprising a peptide according to any of the claims 1-3 and a pharmaceutically acceptable carrier or diluent.
5. A Cancer Vaccine comprising a peptide according to any of the claims 1-3 and a pharmaceutically acceptable carrier or diluent.
6. Use of a peptide according to any of the claims 1-3 for the preparation of a pharmaceutical composition for eliciting T-cell immunity against tumours.
7. Method for vaccination of a person disposed for cancer consisting of induction of T-cell immunity to oncogene proteins by stimulating in vivo with peptides according to the claims 1-3.
8. Method for treatment of a patient afflicted with cancer consisting of induction of T-cell immunity to oncogene proteins by stimulating in vivo or in vitro with peptides according to the claims 1-3.

Abstract

Synthetic peptides and fragments of oncogene protein products which elicit T cellular immunity, for use in cancer vaccines and compositions for anti-cancer treatment.

Protocol:

1/33

2 mill.cells / ml x 10 ml

20 micrograms of five p21 ras peptides

1 week

restimulation: 1 mill.irrad.autologous feeder cells/ml

and 20 micrograms of each peptide final dilution

1 week

restimulation (as described above)

1 week

cloning: 20 Terasaki plates, 1 blast per well

clones in 51 out of 600 wells

Probability of clonality: 97,8 %

45 clones expanded

29 clones characterized

Figure 1

SUBSTITUTE SHEET

2/33





Figure 2a

SUBSTITUTE SHEET

3/33




Figure 2b

SUBSTITUTE SHEET

4/33






Figure 2c



5/33



Clone:



Clone+APC:



Clone+APC+P-44:



Clone+APC+P-45:



Clone+APC+P-42:




Clone+APC+P-43:



Clone+APC+P-46:

Figure 2d

6/33  
**Stimulation of clone F with P-45, P-37, P-38,  
P-39, P-40 and P-41**



Clone: 50000 cells/well

APC: 50000 cells/well

Peptide concentration: 20 micrograms/ml

Figure 2e

7/33

**Clone I:  
Inhibition with the mAb L 243 specific for  
HLA-DR**




Figure 3a

8/33

**Clone B:  
Inhibition with the mAb L 243 specific for  
HLA-DR**





Figure 3b

SUBSTITUTE SHEET

9/33

**Clone E:  
Inhibition with the mAb FN.81.1.1. specific for  
HLA-DQ**



Clone+APC+P-43

Figure 3c

**SUBSTITUTE SHEET**

10/33

**Clone F:**  
**Inhibition with the Moab FN 81.1.1 specific for**  
**HLA-DQ**





Figure 3d

**SUBSTITUTE SHEET**

11/33

# **Inhibition of Clone I with P-20,21,22,23,24,37, 38,39,40,41,42,43,44,45,46:**




The percentages refer to % inhibition

Concentration of inhibiting peptide: 250 micro M  
 Concentration of stimulating peptide: 10 micro M  
 Clone: 50000 cells/well, APC: 50000 cells/well

Figure 4

12/33

# **Inhibition of Clone E with P-20,21,22,23,24,37, 38,39,40,41,42,43,44,45,46:**




Concentration of inhibiting peptide: 250 micro M  
 Concentration of stimulating peptide: 10 micro M  
 Clone: 50000 cells/well, APC: 50000 cells/well

Figure 5



13/33

**Stimulation of clone E with truncated P-43**


Concentration of stimulating peptide: 10 micro M

Clone: 50 000 cells/well

APC: 50000 cells/well

**Figure 6**


14/33

**Inhibition of Clone E with truncated P-43:**

Concentration of inh biting peptide 250 micro M  
Concentration of stimulating peptide 5 micro M  
Clone: 50000 cells/well, APC: 50000 cells/well

**Figure 7**

15/33

**Stimulation of Clone F with truncated P-45**


Clone: 50000 cells/well

APC: 50000 cells/well

Concentration of stimulating peptide: 10 micro M

**Figure 8**

16/33

**Patient nr.29 Follicular thyroid carcinoma:**

PBMC: 100000 cells/well


Peptide concentration: 100 micrograms/ml

IL2 = 1 U/ml

Figure 9

**SUBSTITUTE SHEET**

17/33

**Patient nr.29 Follicular thyroid carcinoma:**

PBMC: 200000 cells/well


P-23 k1 = 20 microg./ml, P-23 k2 = 200 microg./ml

IL2: 1 U/ml

**Figure 10****SUBSTITUTE SHEET**

18/33

**Restimulation with P-20,21,22,23,24 after one  
week bulk culture with peptide 23:**



PBMC: 25000 cells/well


APC: 25000 cells/well

Peptide concentration: 200 microg./ml

Figure 11

19/33

# Peptide 23 specific clones derived from patient nr.29



Clone: 50000 cells/well

APC: irradiated allogeneic HLA-DQ identical PBMC

50000 cells/well

Peptide 23: 50 micrograms/ml


Figure 12

SUBSTITUTE SHEET

20/33

# Peptide 23 specific clones derived from patient nr.29

(continued...)



Clone: 50000 cells/well

APC: irradiated allogeneic HLA-DQ identical PBMC

50000 cells/well

Peptide 23: 50 micrograms/ml

Figure 12


SUBSTITUTE SHEET



21/33

# Peptide 23 specific clones derived from patient nr.29

(continued...)



Clone: 50000 cells/well

APC: irradiated allogeneic HLA-DQ identical PBMC

50000 cells/well

Peptide 23: 50 micrograms/ml


Figure 12

SUBSTITUTE SHEET

22/33

# Peptide 23 specific clones derived from patient nr.29

(continued...)



Clone: 50000 cells/well

APC: irradiated allogeneic HLA-DQ identical PBMC

50000 cells/well


Peptide 23: 50 micrograms/ml

Figure 12

SUBSTITUTE SHEET

23/33

**Clone 14:  
Blocking with the mAb FN 81.1.1.  
specific for HLA-DQ**



Clone+APC+mAb+P-23

Clone: 50000 cells/well


APC: 50000 cells/well

Concentration of P-23: 50 micrograms/ml

Figure 13

**SUBSTITUTE SHEET**

24/33

**Stimulation of Clone 15 with truncated peptides:**


Clone: 50 000 cells/well, APC: 50000 cells/well

C1=20 micro M, C2=50 micro M, C3=100 micro M

Figure 14

25/33

# Stimulation of Clone 14 with P-23, P-100, P-106, P-107, P-108, P-109, P-110, P-111



Clone: 32000 cells/well, APC: 50000 cells/well

C1 = 20 micro M, C2 = 50 micro M, C3 = 100 micro M

Figure 15

26/33




Figure 16

SUBSTITUTE SHEET

27/33


*Clone B, Stimulation with truncated 12 Arg peptides*

Figure 17

28 / 33


*Clone I, Stimulation with truncated 12 Lys peptides*

Figure 17

(continued...)



29 / 33





Figure 18

30/33





Figure 18

(continued...)

SUBSTITUTE SHEET

31/33




Figure 19

SUBSTITUTE SHEET

32/33





Figure 19

(continued...)

SUBSTITUTE SHEET

33/33

# Growth inhibition of HT29 by TLC 14 in the presence of the 61 Leu peptide



HT29 was preincubated with gamma-IFN for 3 days

Figure 20

**SUBSTITUTE SHEET**

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/NO 92/00032

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>1</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 K 13/00, C 07 K 7/10, A 61 K 37/02, A 61 K 39/00																	
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched<sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%; border: 1px solid black;">Classification System</th> <th style="border: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; height: 40px; vertical-align: top;">IPC5</td> <td style="border: 1px solid black; vertical-align: top;">C 07 K; A 61 K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in Fields Searched<sup>8</sup></div> <p>SE,DK,FI,NO classes as above</p>			Classification System	Classification Symbols	IPC5	C 07 K; A 61 K											
Classification System	Classification Symbols																
IPC5	C 07 K; A 61 K																
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 5%; border: 1px solid black;">Category<sup>10</sup></th> <th style="width: 65%; border: 1px solid black;">Citation of Document<sup>11</sup> with indication, where appropriate, of the relevant passages<sup>12</sup></th> <th style="width: 30%; border: 1px solid black;">Relevant to Claim No.<sup>13</sup></th> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">X</td> <td style="border: 1px solid black; vertical-align: top;">J.EXP.MED., Vol. 173, 1991 Stefan Jung et al: "Human T Lymphocytes Recognize a Peptide of Single Point-mutated, Oncogenic ras Proteins", see page 273 - page 276 --</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-6</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">X</td> <td style="border: 1px solid black; vertical-align: top;">WO, A1, 9001701 (PROGENX, INC.) 22 February 1990, see especially table 1 polypeptide no 141, 232, 143, 144, 145, 231 --</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-6</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">X</td> <td style="border: 1px solid black; vertical-align: top;">US, A, 4898932 (CARNEY) 6 February 1990, see especially the abstract, column 4 lines 20-34 --</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-6</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top;">X</td> <td style="border: 1px solid black; vertical-align: top;">WO, A1, 8910565 (E.I. DU PONT DE NEMOURS AND COMPANY) 2 November 1989, see especially page 10 line 14 - page 26 line 10 --</td> <td style="border: 1px solid black; text-align: center; vertical-align: top;">1-6</td> </tr> </table>			Category <sup>10</sup>	Citation of Document <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X	J.EXP.MED., Vol. 173, 1991 Stefan Jung et al: "Human T Lymphocytes Recognize a Peptide of Single Point-mutated, Oncogenic ras Proteins", see page 273 - page 276 --	1-6	X	WO, A1, 9001701 (PROGENX, INC.) 22 February 1990, see especially table 1 polypeptide no 141, 232, 143, 144, 145, 231 --	1-6	X	US, A, 4898932 (CARNEY) 6 February 1990, see especially the abstract, column 4 lines 20-34 --	1-6	X	WO, A1, 8910565 (E.I. DU PONT DE NEMOURS AND COMPANY) 2 November 1989, see especially page 10 line 14 - page 26 line 10 --	1-6
Category <sup>10</sup>	Citation of Document <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>															
X	J.EXP.MED., Vol. 173, 1991 Stefan Jung et al: "Human T Lymphocytes Recognize a Peptide of Single Point-mutated, Oncogenic ras Proteins", see page 273 - page 276 --	1-6															
X	WO, A1, 9001701 (PROGENX, INC.) 22 February 1990, see especially table 1 polypeptide no 141, 232, 143, 144, 145, 231 --	1-6															
X	US, A, 4898932 (CARNEY) 6 February 1990, see especially the abstract, column 4 lines 20-34 --	1-6															
X	WO, A1, 8910565 (E.I. DU PONT DE NEMOURS AND COMPANY) 2 November 1989, see especially page 10 line 14 - page 26 line 10 --	1-6															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 50%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p> </div> </div>																	
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border: 1px solid black; vertical-align: top;">           Date of the Actual Completion of the International Search             5th June 1992         </td> <td style="width: 50%; border: 1px solid black; vertical-align: top;">           Date of Mailing of this International Search Report             1992-06-10         </td> </tr> <tr> <td style="border: 1px solid black; vertical-align: top;">           International Searching Authority   <div style="text-align: center;"> <b>SWEDISH PATENT OFFICE</b> </div> </td> <td style="border: 1px solid black; vertical-align: top;">           Signature of Authorized Officer             Mikael G. son Bergstrand         </td> </tr> </table>			Date of the Actual Completion of the International Search  5th June 1992	Date of Mailing of this International Search Report  1992-06-10	International Searching Authority  <div style="text-align: center;"> <b>SWEDISH PATENT OFFICE</b> </div>	Signature of Authorized Officer Mikael G. son Bergstrand											
Date of the Actual Completion of the International Search  5th June 1992	Date of Mailing of this International Search Report  1992-06-10																
International Searching Authority  <div style="text-align: center;"> <b>SWEDISH PATENT OFFICE</b> </div>	Signature of Authorized Officer Mikael G. son Bergstrand																

Form PCT/ISA/210 (second sheet) (January 1988)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	WO, A1, 8908710 (E.I. DU PONT DE NEMOURS AND COMPANY) 21 September 1989, see the abstract, claims 1-2 ---	1-6
X	WO, A1, 8904489 (PROGENX, INC.) 18 May 1989, see especially table 1 ---	1-6
X	EP, A2, 0190033 (E.I. DU PONT DE NEMOURS AND COMPANY) 6 August 1986, see the abstract ---	1-6
X	WO, A1, 8500807 (SCRIPPS CLINIC AND RESEARCH FOUNDATION) 28 February 1985, see especially claim 5 ---	1-6
X	EP, A1, 0108564 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 16 May 1984, see especially claim 17 ---	1-6
X	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 160, No. 1, 1989 Chien-Hua Niu et al: "Comparison of the conformation and GTP hydrolysing ability of N-terminal ras p 21 protein segments", see page 282 - page 288 see especially page 283 lines 2-7 ---	1-6
X	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 157, No. 2, 1988 P.A. Longo et al: "The structure of the amino terminal transforming segment of the p21 protein, Tyr4-Thr20 (with Asp12), by two-dimensional NMR", see page 776 - page 782 see especially page 777 lines 21-32 ---	1-6
X	PROC.NATL.ACAD.SCI., Vol. 82, 1985 Takeo Tanaka et al: "Efficient generation of antibodies to oncoproteins by using synthetic peptide antigens", see page 3400 - page 3404 see especially table 1 ----- -----	1-6

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 7-8, because they relate to subject matter not required to be searched by this Authority, namely:

Methods for treatment of the human or animal body  
c.f. PCT RULE 39.9.

2. ☒ Claim numbers 1, 4-6 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

These claims relate to peptides derived from unspecific oncogenes having an unspecific point of mutation or translocation. The amount of information in these claims is not sufficient to make a complete search and hence, the claims are considered to be unacceptable according to PCT article 6. The search has been restricted to peptides derived from the p 21 ras protein.

3. ☐ Claim numbers \_\_\_\_\_, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the the claims. It is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.PCT/NO 92/00032**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 30/04/92. The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9001701	90-02-22	EP-A- 0354808 JP-T- 4500122	90-02-14 92-01-09
US-A- 4898932	90-02-06	US-A- 5084380 EP-A- 0190033 JP-A- 61180799	92-01-28 86-08-06 86-08-13
WO-A1- 8910565	89-11-02	AU-D- 3447989 EP-A- 0411018 JP-T- 3505250	89-11-24 91-02-06 91-11-14
WO-A1- 8908710	89-09-21	EP-A- 0370012	90-05-30
WO-A1- 8904489	89-05-18	AU-D- 2497388 EP-A- 0318179 JP-T- 3500928	89-05-11 89-05-31 91-02-28
EP-A2- 0190033	86-08-06	JP-A- 61180799 US-A- 4898932	86-08-13 90-02-06
WO-A1- 8500807	85-02-28	AU-B- 580738 AU-D- 3386089 AU-D- 3395084 CA-A- 1219232 EP-A- 0152477 JP-T- 61500068 US-A- 5015571 US-A- 5030565	89-02-02 89-08-24 85-03-12 87-03-17 85-08-28 86-01-16 91-05-14 91-07-09
EP-A1- 0108564	84-05-16	AU-B- 559912 AU-D- 2065083 CA-A- 1252046 DE-A- 3376507 JP-A- 59113898 US-A- 4699877	87-03-26 84-05-10 89-04-04 88-06-09 84-06-30 87-10-13